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Abstract
Alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), cause disease in both equine and humans that exhibit
overt encephalitis in a significant percentage of cases. Features of the host immune response and tissue-specific responses
may contribute to fatal outcomes as well as the development of encephalitis. It has previously been shown that VEEV
infection of mice induces transcription of pro-inflammatory cytokines genes (e.g., IFN-c, IL-6, IL-12, iNOS and TNF-a) within
6 h. GSK-3b is a host protein that is known to modulate pro-inflammatory gene expression and has been a therapeutic
target in neurodegenerative disorders such as Alzheimer’s. Hence inhibition of GSK-3b in the context of encephalitic viral
infections has been useful in a neuroprotective capacity. Small molecule GSK-3b inhibitors and GSK-3b siRNA experiments
indicated that GSK-3b was important for VEEV replication. Thirty-eight second generation BIO derivatives were tested and
BIOder was found to be the most potent inhibitor, with an IC50 of ,0.5 mM and a CC50 of .100 mM. BIOder was a more
potent inhibitor of GSK-3b than BIO, as demonstrated through in vitro kinase assays from uninfected and infected cells. Size
exclusion chromatography experiments demonstrated that GSK-3b is found in three distinct complexes in VEEV infected
cells, whereas GSK-3b is only present in one complex in uninfected cells. Cells treated with BIOder demonstrated an increase
in the anti-apoptotic gene, survivin, and a decrease in the pro-apoptotic gene, BID, suggesting that modulation of pro- and
anti-apoptotic genes contributes to the protective effect of BIOder treatment. Finally, BIOder partially protected mice from
VEEV induced mortality. Our studies demonstrate the utility of GSK-3b inhibitors for modulating VEEV infection.
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Introduction
Arthropod-borne viruses are important causes of acute
encephalitis and an emerging worldwide problem with significant
risk for importation into new regions [1,2]. Alphaviruses, including
Venezuelan Equine Encephalitis Virus (VEEV), cause disease in
both equine and humans that exhibit overt encephalitis in a
significant percentage of cases. VEEV can be present in both
enzootic and epizootic strains, which are critically different.
Enzootic strains of VEEV cycle between Culex mosquitoes and
rodents. Horses do not serve as amplifying hosts for the enzootic
VEEV and generally do not become ill due to infection. In
contrast, horses are highly susceptible to epizootic VEEV (IA/B
and IC subtypes), resulting in high rates of mortality (20–80%) [3].
Importantly, horses amplify the viruses, and the resulting high
viremia, permits mosquito transmission, increasing equine disease
and also allowing the transmission to humans. For example, in
1995, VEEV re-emerged in Venezuela and Colombia causing an
epidemic of 75,000–100,000 human cases [4]. The increased
circulation and spread of encephalitic arboviruses underscores the
need for understanding the pathogenesis of viral encephalomyelitis
and identification of useful interventions.
The incubation period for VEEV is usually 2–5 days [5]. VEEV
infections lead to symptoms such as malaise, fever, chills, and
severe retro-orbital or occipital headache [5]. Symptoms of central
nervous system involvement do not occur as frequently, but may
include convulsions, somnolence, confusion, and photophobia.
VEEV infection in humans is lethal in a small percent of cases (less
than 1%), with most of these cases being observed in children [6].
Neurological disease, including disorientation, ataxia, mental
depression, and convulsions, occurs in up to 14% of infected
individuals and neurological sequelae are common [7]. VEEV can
also cause infection by the respiratory route and has previously
been weaponized [8]. There is currently no specific antiviral
therapeutics for the treatment of VEEV. There is a live attenuated
vaccine, TC-83, which can be used for equines and is in limited
use in the US under an IND (for military and at risk laboratory
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personnel only). Unfortunately, the vaccine is not FDA approved
and has a high frequency of adverse events associate with its use.
Therefore, treatment options are severely limited and drug
development is an area in need of a breakthrough.
VEEV is a cytoplasmically replicating virus that buds from the
plasma membrane. It is an enveloped non-segmented positive
stranded RNA virus. Its genome is approximately 11 kb in length
and encodes two open reading frames (ORF). ORF1 encodes 4
nonstructural proteins (nsP1, nsP2, nsP3, and nsP4), which play
critical roles in viral replication and protein processing [9,10].
nsP1 is responsible for the capping and methylation of the viral
plus-strand RNAs and for the regulation of minus strand RNA
synthesis [11]. nsP2 is the viral protease responsible for cleavage of
the P1234 polyprotein and also contains helicase activity
[11,12,13]. nsP3 is a phospho-protein that is also important for
minus strand RNA synthesis, through a yet to be discovered
mechanism. nsP4 is the RNA dependent RNA polymerase
[14,15]. ORF2 encodes 5 structural proteins, the capsid, the
envelope glycoproteins (E1, E2, and E3), and the 6,000-molecular-
weight (6K) protein [10]. Many of the functional roles of the viral
proteins have been studied in model alphaviruses, such as Sindbis
and Ross River Viruses. For VEEV, there have been a number of
studies on the capsid protein, demonstrating its ability to inhibit
host transcription [16] as well as nuclear import [17,18].
VEEV infection results in CNS inflammation, including the
induction of pro-inflammatory cytokines such as interleukin-1b
(IL-1b), IL-6, IL-12, and tumor necrosis factor -a (TNF-a)
[19,20,21,22]. The inflammatory response contributes to neuro-
degeneration following encephalitic virus infection. Interestingly,
many of the same cytokines are influenced by glycogen synthase
kinase-3b (GSK-3b) activity. Specifically, GSK-3b activity is
necessary for the production of the pro-inflammatory cytokines,
IL-6, IL-1b, and TNF, and reduction of the anti-inflammatory
cytokine IL-10 [23]. GSK-3 is a serine/threonine protein kinase
that is implicated in energy homeostasis, insulin signaling,
proliferation, apoptosis, neurobiology, development, and immu-
nology [24,25]. There has been much interest in inhibiting GSK-
3b for the treatment of Alzheimer’s disease, and other neurological
disorders, due to its ability to phosphorylate the microtubule
associated Tau protein [26,27] as well as influence inflammation
[28,29,30]. Moreover, GSK-3b inhibitors such as lithium, SB
216763, SB 415286, and BIOder can protect neurons from
apoptosis [31,32]. Interestingly, GSK-3b is also important for viral
replication of some viruses, such as HIV and influenza [32,33].
Knockdown of GSK-3b or inhibition through small molecule
compounds, BIO or BIOder, inhibits HIV replication and Tat-
dependent transcription [32]. Therefore, we sought to examine the
importance of GSK-3b for VEEV replication and pathogenesis.
Here we present data on small molecule inhibitors that can inhibit
both VEEV replication and VEEV induced cell death. These
small chemical molecules are inhibitors of GSK-3b, which is
known to have important implications in inflammation and
neurological disease. Specifically, BIOder partially protected mice
from VEEV mortality, emphasizing the role for GSK-3b in VEEV
replication and pathogenesis.
Materials and Methods
Viruses
VEEV TC-83 was obtained from BEI resources. The TC-83
virus is a live attenuated vaccine derivative of the Trinidad donkey
(TRD) strain of VEEV that was derived by 83 serial passages of
the virus in guinea pig heart cells [34]. The genomes of TRD and
TC-83 differ at 12 nucleotide positions and the attenuation of TC-
83 has been mapped to changes in the 59-noncoding region and
the E2 envelope glycoprotein [35]. The replication of TC-83 has
been well studied both in vitro and in vivo and is a BSL-2 model for
the fully virulent BSL-3 TRD VEEV.
Small Molecule Compounds
The BIO derivatives used in this study were: 1: 2-{[[2-(5-
bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino](oxo)ace-
tyl]amino}benzoic acid, 2: N9,1,,N9,4,-bis(5-methyl-2-oxo-
1,2-dihydro-3H-indol-3-ylidene)terephthalohydrazide, 3: 5-bro-
mo-3-({2-[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)amino]pheny-
l}imino)-1,3-dihydro-2H-indol-2-one, 4: 4-bromo-5-methyl-1H-
indole-2,3-dione 3-oxime, 5: 4-bromo-5-methyl-1H-indole-2,3-
dione 3-(N-phenylsemicarbazone), 6: 6-bromo-5-methyl-1H-in-
dole-2,3-dione 3-[(6-bromo-5-methyl-2-oxo-1,2-dihydro-3H-in-
dol-3-ylidene)hydrazone], 7: N9-(5-bromo-7-methyl-2-oxo-1,2-di-
hydro-3H-indol-3-ylidene)-2-chlorobenzohydrazide, 8: N9-(5-
bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2- chlorobenzohy-
drazide, 9: 5,7-dibromo-1H-indole-2,3-dione 3-(phenylhydra-
zone), 10: 5,7-dibromo-1H-indole-2,3-dione 3-oxime, 11: 2-
chloro-N9-(5,7-dibromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-
benzohydrazide, 12: 2-bromo-N9-(5,7-dibromo-2-oxo-1,2-dihy-
dro-3H-indol-3-ylidene)benzohydrazide, 13: N9-(4-bromo-5-meth-
yl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-3,5-dihydroxybenzohy-
drazide, 14: N9-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-
2-methyl-3-furohydrazide, 15: N-(1-{[2-(5-fluoro-2-oxo-1,2-dihy-
dro-3H-indol-3-ylidene)hydrazino]carbonyl}-2-phenylvinyl)benza-
mide, 16: N9-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-
2,4-dichlorobenzohydrazide, 17: 4-bromo-5-methyl-1H-indole-
2,3-dione 3-(phenylhydrazone), 18: 6-chloro-7-methyl-1H-indole-
2,3-dione 3-oxime, 19: 4-chloro-7-methyl-1H-indole-2,3-dione 3-
oxime, 20: 3-[(1H-indazol-5-ylamino)methylene]-1,3-dihydro-2H-
indol-2-one, 21: 2-(5-bromo-2-methyl-1H-indol-3-yl)-N9-(2-oxo-
1,2-dihydro-3H-indol-3-ylidene)acetohydrazide, 22: N9-(2-oxo-
1,2-dihydro-3H-indol-3-ylidene)-3-phenyl-1H-pyrazole-5-carbo-
hydrazide, 23: N9-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-yli-
dene)-3-phenyl-1Hpyrazole-5-carbohydrazide, 24: N9-(5,7-di-
bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-3-phenyl-1Hpyra-
zole-5-carbohydrazide, 25: N-[1-{[2-(5-bromo-2-oxo-1,2-dihydro-
3H-indol-3-ylidene)hydrazino]carbonyl}-2-(3,4-dimethoxyphe-
nyl)vinyl]benzamide, 26: N-[1-{[2-(5-bromo-7-methyl-2-oxo-1,2-
dihydro-3H-indol-3-ylidene)hydrazino]carbonyl}-2-(2,5-di-
methoxyphenyl)vinyl]benzamide, 27: 3-(4-methoxyphenyl)-N9-(2-
oxo-1,2-dihydro-3H-indol-3-ylidene)-1Hpyrazole-5-carbohydra-
zide, 28: N9-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-3-
(4-methoxyphenyl)-1H-pyrazole-5-carbohydrazide, 29: 3-(4-ethox-
yphenyl)-4-methyl-N9-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)-
1H-pyrazole-5-carbohydrazide, 30: 3-(2-naphthyl)-N9-(2-oxo-1,2-
dihydro-3H-indol-3-ylidene)-1H-pyrazole-5-Carbohydrazide, 31:
N-(2-{[2-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazi-
no]carbonyl}phenyl)benzamide, 32: N9-(5-bromo-2-oxo-1,2-dihy-
dro-3H-indol-3-ylidene)-3-methyl-1Hpyrazole-5-carbohydrazide,
33: 5-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)-2,4-imida-
zolidinedione, 34: 5-bromo-59-chloro-3,39-biindole-2,29(1H,19H)-
dione, 35: 5-chloro-3,39-biindole-2,29(1H,19H)-dione, 36: 5-fluoro-
3,39-biindole-2,29(1H,19H)-dione, 37: 5-bromo-7-methyl-3,39-
biindole-2,29(1H,19H)-dione, 38: 6-chloro-7-methyl-3,39-biindole-
2,29(1H,19H)-dione. All inhibitors were prepared in 10 mM stock
solution dissolved in DMSO.
Drug Treatments and Plaque Assay
U87MG cells were seeded at 10,000 cells per well in a 96-well
plate, pretreated for 2 hrs with DMSO (final concentration of 1%)
or small molecule compounds in growth media. Cultured cells
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were then infected with VEEV TC83 at an MOI of 0.1. One hour
later, viral inoculums were removed, cells washed two times with
PBS, and growth media supplemented with the small molecule
inhibitors added. Supernatants were collected at 24 hours post-
infection and analyzed by plaque assays. For plaque assays, Vero
cells were plated in 6 well plates at 16106. When cells reached
90% to 100% confluency, they were infected as follows in
duplicates for each dilution. Viral supernatants were diluted 1:10
in complete DMEM media from 1021 to 10211. Four hundred ml
of each viral dilution was added to the cells. After the one hour
infection an overlay of 3 ml of a 1:1 solution of 0.5% agarose in
diH20 with 26EMEM for plaque assays, containing 5% FBS, 1%
L-Glutamine, 2% penicillin/streptomycin, 1% nonessential amino
acids, and 1% sodium pyruvate was added to each well, allowed to
solidify and incubated at 37uC at 5% CO2 for 48 hrs. After 48 hrs,
cells were fixed using 4% formaldehyde for 1 hr at room
temperature. The agar plugs were then discarded and fixed
cellular monolayers were stained with a 1% crystal violet, 20%
methanol solution for 15 min, visualizing plaques. Averages were
taken from duplicates, with dilutions containing fewer than 5 or
more than 100 plaques being discounted. The viral titer was
calculated as follows: pfu/ml = average of 2 plaque counts62.5
(dilution factor)6dilution.
MTT Assay
Ten thousand U87MG cells were plated per well in a 96-well
plate and the next day cells were treated with 1 mM compound or
DMSO. Two hours later, cells were infected with VEEV TC83 at
an MOI of 0.1 for one hour. Following infection, medium
containing compounds were added back to the cells. MTT assay
were performed 48 or 72 hours post-infection. For MTT assays,
10 ml MTT reagent (50 mg/ml) was added to each well and plates
incubated at 37uC for 2 hours. Next, 100 ml of DMSO was added
to each well and the plate was shaken for 15 minutes at room
temperature. The assay was read at 590 nM using a DXT 880
plate reader (Beckman Coulter).
Quantitative RT-PCR
U87MG cells were infected with VEEV at an MOI of 0.1.
Twenty-four hours later, supernatants were collected for analysis
of viral RNA. Viral RNA was extracted using Ambion’s MagMax
viral RNA extraction kit and quantitated using q-RT-PCR with
primers and probe for nucleotides 7931–8005 of VEEV TC-83.
TC-83 RNA was amplified (1 cycle- 50uC for 30 min, 1 cycle
95uC for 2 min and 40 cycles- 95uC for 15 sec and 61uC for
60 sec) using the ABI Prism 7000. Primer-pairs (forward
TCTGACAAGACGTTCCCAATCA, reverse GAA-
TAACTTCCCTCCGACCACA) and Taq-man probe (59 6-
carboxyfluorescein-TGTTGGAAGGGAAGATAAACGGC-
TACGC-6-carboxy-N,N,N9,N9-tetramethylrhodamine-39) were
originally described by Julander et al. [36]. Q-RT-PCR assays
were performed using Invitrogen’s RNA UltraSenseTM One-Step
Quantitative RT-PCR System. The absolute quantification was
calculated based on the threshold cycle (Ct) relative to the
standard curve.
Immunoprecipitation and In Vitro Kinase Assay
For immunoprecipitation (IP) 2 mg of extract from BIO or
BIOder-treated (0.1, 1.0 mM) U87MG or Vero cells were
immunoprecipitated at 4uC overnight with GSK-3b antibody.
The next day complexes were precipitated with A/G beads
(Calbiochem) for two hours at 4uC. IPs were washed twice with
appropriate TNE buffer and kinase buffer. Reaction mixtures
(20 ml) contained final concentrations: 40 mM b-glycerophosphate
pH 7.4, 7.5 mM MgCl2, 7.5 mM EGTA, 5% glycerol, [c-
32P]ATP (0.2 mM, 1 mCi), 50 mM NaF, 1 mM orthovanadate,
and 0.1% (v/v) b-mercaptoethanol. Phosphorylation reactions
were performed with IP material and 200 ng of glycogen synthase
peptide 2 (Millipore) as substrate in TTK kinase buffer containing
50 mM HEPES (pH 7.9), 10 mM MgCl2, 6 mM EGTA, and
2.5 mM dithiothreitol. Reactions were incubated at 37uC for
1 hour and stopped by the addition of 1 volume of Laemmli
sample buffer containing 5% b-mercaptoethanol and analyzed by
SDS-PAGE on a 4–20% gel. Gels were subjected to autoradiog-
raphy and quantitation using Molecular Dynamics PhosphorIma-
ger software (Amersham Biosciences, Piscataway, NJ, USA).
RT-PCR Analysis
Total cellular RNA was extracted using Qiagen’s RNeasy RNA
extraction kit as per manufacturer’s instructions. Approximately
1.0 ug of RNA was utilized to generate cDNA using iScript cDNA
Synthesis kit (Bio-Rad) and oligo-dT reverse primers according to
the manufacturer’s instructions. The resultant cDNA was utilized
in a standard PCR reaction with primers against the pro- and anti-
apoptotic genes indicated (primers listed in Table 1). PCR
reactions were carried as follows: 94uC for 2 mins, 35 cycles of
95uC for 30 seconds, 54uC for 30 seconds, and 72uC for 1 minute,
followed by a final 10 minute 72uC extension time. Amplified
products were separated in 1% agarose gels stained with ethidium
bromide and visualized using the Bio Rad Molecular Imager
ChemiDoc XRS system (Bio-Rad). Band intensities were calcu-
lated using Quantity One 4.6.5 software (Bio Rad).
Size-exclusion Chromatography
U87MG cells were infected with VEEV (MOI 1.0) and cells
were pelleted for analysis at approximately 20 hours post infection.
Cell pellets were washed twice with phosphate-buffered saline
(PBS) without Ca2+ and Mg2+ and resuspended in lysis buffer
Table 1. Pro- and anti-apoptotic primer sequences used for
RT-PCR.
Gene Primer Sequence
Bcl2 Forward AGGAAGTGAACATTTCGGTGAC
Reverse GCTCAGTTCCAGGACCAGG
Survivin Forward TTTCTCAAGGACCACCGCAT
Reverse CCAGCTCCTTGAAGCAGAAGAA
cIAP Forward TGGGAAGCTCAGTAACTGGGAA
Reverse GCATGTGTCTGCATGCTCAGAT
Bcl-XL Forward ATGGCAGCAGTAAAGCAAGC
Reverse CGGAAGAGTTCATTCACTACCTGT
BID Forward ACACTGTGAACCAGGAGTGAGT
Reverse AACAGCTTTGGAGGAAGCCA
BAK Forward TGGTCACCTTACCTCTGCAA
Reverse TCAAACAGGCTGGTGGCAAT
BAX Forward TGCTTCAGGGTTTCATCCAG
Reverse GGCGGCAATCATCCTCTG
BAD Forward AACCAGCAGCAGCCATCAT
Reverse CCACAAACTCGTCACTCATCCT
GAPDH Forward GGAAGGTGAAGGTCGGAGTCAA
Reverse CCTTGACGGTGCCATGGAAT
doi:10.1371/journal.pone.0034761.t001
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[50 mM Tris–HCl (pH 7.5), 120 mM NaCl, 5 mM ethylenedi-
aminetetraacetic acid, 0.5% NP-40, 50 mM NaF, 0.2 mM
Na3VO4, 1 mM DTT, and one complete protease cocktail
tablet/50 mL] and incubated on ice for 20 minutes, with gentle
vortexing every 5 minutes. Lysates were then centrifuged at 4uC at
10,000 rpm for 10 minutes. Supernatants were transferred to a
fresh tube and protein concentrations were determined using the
Bradford protein assay (BioRad, Hercules, CA). Two milligrams of
protein from each treatment was equilibrated and degassed in
chromatography running buffer [0.2 M Tris–HCl (pH 7.5), 0.5 M
NaCl, and 5% glycerol]. The lysates were run on a Superose 6 HR
10/30 size-exclusion chromatography column using the AKTA
purifier system (GE Healthcare, Piscataway, NJ, USA). Flow-
through was collected at 4uC at a flow rate of 0.3 mL/minute at
0.5 mL for approximately 70 fractions. Every 5th fraction was
acetone precipitated (,250 ul) using 4 volumes of ice-cold 100%
acetone, incubating for 15 minutes on ice. Lysates were centri-
fuged at 4uC f or 10 minutes at 12,000 rpm, supernatants were
removed, and the pellets were allowed to dry for a few minutes at
room temperature. The pellets were resuspended in Laemmli
buffer and analyzed by immunoblotting for GSK-3b and actin
antibodies.
Animal Experiments
Six to eight week old female C3H/HeN mice were obtained
from Charles River Laboratories, Wilmington, MA. All experi-
ments were carried out in bio-safety level 2 (BSL-2) facilities and in
accordance with the Guide for the Care and Use of Laboratory
Animals (Committee on Care And Use of Laboratory Animals of
The Institute of Laboratory Animal Resources, National Research
Council, NIH Publication No. 86–23, revised 1996). The animal
experiments were performed under GMU IACUC protocol
#0211. For toxicity experiments, female C3H/HeN mice were
treated subcutaneously with either DMSO or various concentra-
tion of BIOder (10 mg/kg, 20 mg/kg, 40 mg/kg) every day for 5
days. Mice were weighed daily and monitored for morbidity and
mortality, including lethargy and ruffled fur. For infection
experiments, female C3H/HeN mice were infected intranasally
with 56LD50 (26107 pfu) of VEEV TC-83. Groups of 10 mice
were treated subcutaneously with vehicle, BIO (50 mg/kg) or
BIOder (20 mg/kg) on days 21, 1, 3, and 5 and were monitored
for survival for 14 days. Significance was determined using
Mantel-Cox Log-rank test.
Results
Small molecule inhibitors of GSK-3b impede VEEV
replication
GSK-3b has been shown to be important for viral replication
for viruses such as HIV and influenza [32,33]. Therefore, we
asked the question if GSK-3b inhibitors, such as BIO [37], SB
415286 [38,39], and SB 216763 [39], could inhibit VEEV
replication. First we assessed the effect of BIO treatment on
U87MG viability. U87MG cells were treated with various
concentrations of BIO (10, 5, 2.5, and 1.25 mM) and cell viability
examined 24 hours post-treatment. Treatment of cells with
#5 mM of BIO did not result in any significant decrease in cell
viability (Figure 1A). Non-toxic concentrations of BIO were then
utilized to determine the influence of BIO on VEEV replication.
U87MG cells were pre-treated with BIO, followed by infection
with VEEV TC-83, and post-treatment with compounds. Viral
supernatants were collected 24 hours post-infection and viral
replication assayed by plaque assays (Figure 1B). BIO inhibited
VEEV replication in a dose dependent manner, with greater than
2 logs of inhibition observed at 5 mM (Figure 1B). A similar set of
experiments were performed with SB 415286, and SB 216763. Up
to 50 mM of SB 415286 and SB 216763 could be utilized without
inducing cellular toxicity (Figure 1C). Plaque assays performed
with supernatants obtained from SB 415286 and SB 216763
treated cells also demonstrated a dose dependent inhibition of
VEEV replication (Figure 1D). The inhibition observed with SB
415286 and SB 216763 was ,1 log, whereas BIO treatment
resulted in ,2 log inhibition of viral replication. To confirm the
importance of GSK-3b for VEEV replication, siRNA experiments
were performed. U87MG cells were transfected with negative
control siRNA (siNEG) or siRNA against GSK-3b (siGSK3) and
infected with VEEV 48 hours post-transfection. Viral supernatants
were collected 24 hours post-infection and analyzed by plaque
assays (Figure 1E). Western blot was performed and results are
displayed below the graph in Figure 1E, indicating that GSK-3b
expression was decreased following siRNA treatment. Loss of
GSK-3b resulted in greater than 1 log inhibition of VEEV
replication. Collectively, these results indicate that GSK-3b is
utilized for VEEV replication and that loss of GSK-3b activity
impedes VEEV replication.
Identification of a BIO derivative that inhibits VEEV
replication and cytopathic effect
Due to the results obtained with BIO, we sought to identify
more potent BIO derivatives that could inhibit VEEV. Hit2Lead
(Hit2Lead.com) was utilized to identify 38 commercially available
BIO derivatives. The derivatives were tested by q-RT-PCR to
determine their ability to inhibit VEEV replication. For these
experiments, U87MG cells were pretreated with compounds
(1 mM), infected with VEEV TC-83, and post-treated with
compounds. Viral supernatants were collected 24 hours post-
infection and assayed for viral replication by q-RT-PCR.
Derivatives #6, #8, #10, #16, #19, and #20 demonstrated
the greatest inhibition of viral replication, decreasing viral
replication by more than 1 log (10 fold). To confirm that the
inhibition observed was not due to cellular toxicity, cell viability
assays were performed on all derivatives. Results in Figure 2B
indicate that most compounds had little to no effect on cellular
viability. However, compound #16 demonstrated significant
toxicity and compounds #32, #33, and #34 also displayed a
decrease in cellular viability at 1 mM. These compounds were
therefore excluded from further studies. Confirmation plaque
assays were performed with the BIO derivates that displayed the
greatest inhibition of viral replication, without inducing cellular
toxicity (compounds #6, #8, #10, and #19). All compound
displayed at least a log reduction in viral replication (Figure 2C),
confirming their ability to inhibit VEEV viral replication.
GSK-3b inhibitors have been shown to increase proliferation
and protect against cell death [40,41]. This is especially important
for neurons, as they are a non-replenishable cell population within
the human body. Therefore, we were also interested in identifying
BIO derivatives that could protect cells from the cytopathic effect
(CPE) observed upon VEEV infection. All 38 BIO derivatives
were assayed for their ability to protect cells from VEEV induced
CPE. Infected cells displayed ,50% decrease in cell viability
(Figure 2D) as compared to mock infected untreated cells. Many of
the derivatives showed minimal effect on CPE inhibition and some
derivatives actually increased the observed CPE (derivatives 5 and
24). However, a few derivatives could inhibit CPE (derivatives 6,
17, 28, 31). Derivative #6 showed particularly strong inhibition of
VEEV induced CPE as compared to all the other compounds.
These results coupled with the viral replication inhibition data,
suggest that derivative #6 could be an interesting VEEV
Modulation of GSK3-b Activity in VEEV Infection
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34761
therapeutic candidate based on its ability to inhibit both viral
replication and viral induced CPE.
Characterization of BIOder
The structures of BIO and derivative #6 (herein referred to as
BIOder) are displayed in Figure 3A. To further characterize
BIOder’s therapeutic potential, multiple concentrations of BIOder
were utilized and viral replication, viral induced CPE and cellular
toxicity assayed. BIOder inhibited VEEV replication in a dose-
dependent manner (Figure 3B) with an IC50 of ,0.5 mM. To
determine the ability of BIOder to inhibit viral induced cell death,
MTT assays were performed to assess cell viability 72 hours post-
infection. Cells infected with VEEV and treated with DMSO
displayed a reduction in cellular viability by ,50% (Figure 3C).
BIOder treated cells exhibited an increase in cellular viability at all
concentrations tested, however a more pronounced effect was
observed with 1.0 and 0.1 mM of BIOder (Figure 3C). A decrease
in CPE could also be observed via light microscopy imaging with
both BIO and BIOder at 48 hours post-infection (Figure S1).
Importantly, mock infected cells treated with BIOder displayed no
inhibition of cellular viability. In fact, an increase in U87MG
proliferation was observed when cells were treated with all
concentrations of BIOder (Figure 1D). U87MG cells could be
treated with up to 100 mM BIOder with no effect on cellular
viability (data not shown). This is in agreement with the pro-
proliferative activity of GSK-3b inhibitors [42]. These results
indicated that the IC50 for BIOder inhibition of VEEV induced
CPE is ,0.1 mM and the CC50 .100 mM, making BIOder a
promising candidate for future studies. Collectively, these results
indicated that BIOder is an inhibitor of VEEV induced CPE and
VEEV replication.
BIO and BIOder inhibit GSK-3b in VEEV infected cells
We performed a series of kinase assays to determine the
specificity and effectiveness of both BIO and BIOder on GSK-3b
from infected and uninfected cells. Both U87MG (Figure 4A) and
Vero (Figure 4B) cells were infected with VEEV at MOI of 0.1.
Cells were pre- and post-treated with compounds and collected
24 hours post infection. Cell were then lysed and immunoprecip-
itated with control IgG or GSK-3b antibody. Immunoprecipitates
were then bound to protein A and G agarose beads, washed and
used for in vitro kinase assays. A glycogen synthase peptide was used
as a substrate. No kinase activity was observed when uninfected or
infected cells were immunoprecipitated with an IgG control
antibody (lanes 1 and 5). However, the GSK-3b antibody
immunoprecipitations from DMSO treated cells displayed a
robust phosphorylation of the glycogen synthase peptide (lanes 2
and 6). Cells treated with BIO displayed a slight decreased in
kinase activity (lane 3 and 7). In contrast, treatment BIOder had a
much more dramatic influence on the kinase activity of GSK-3b
(lanes 4, 9, and 10). Interestingly, GSK-3b immunoprecipitated
from infected cells was more susceptible to BIOder treatment
(compare lanes 4 and 10). The effective inhibition was seen in both
U87MG and Vero cells, which further implies that BIOder may
be the better therapeutic candidate. To ensure that we in fact
immunoprecipitated GSK-3b protein in these experiments, we
western blotted the IP material for presence of GSK-3b (Panel A
and B) and also ran the samples on a gel and stained for all
proteins present. Results in panel C indicated that specific GSK-
Figure 1. Small molecule inhibitors of GSK-3b impede VEEV replication. A) U87MG astrocytes were treated with BIO (10, 5, 2.5, or 1.25 mM)
and cell viability assayed 24 hours later by CellTiter Glo Assay (Promega). DMSO treated cells are displayed at 100% viability and all treatments
compared to those values. B) U87MG astrocytes were pretreated for 2 hours with DMSO, or BIO (5, 2.5, or 1.25 mM), infected with VEEV TC-83 at MOI
0.1, and post-treated with compounds. Twenty-four hours post infection viral supernatants were collected and assayed for viral replication by plaque
assays. C) U87MG astrocytes were treated with DMSO, SB 415286 (50, 10, or 2 mM), or SB 216763 (50, 10, or 2 mM) and cell viability assayed 24 hours
later by CellTiter Glo Assay (Promega). DMSO treated cells are displayed at 100% viability and all treatments compared to those values. D) U87MG
astrocytes were pretreated for 2 hours with DMSO, SB 415286 (50, or 10 mM), or SB 216763 (50 or 10 mM), infected with VEEV TC-83 at MOI 0.1, and
post-treated with compounds. Twenty-four hours post infection viral supernatants were collected and assayed for viral replication by plaque assays.
E) U87MG astrocytes were transfected with negative control siRNA (siNEG) or GSK-3b siRNA (siGSK3) at 50 nM. Forty-eight hours post-transfection,
cells were infected with VEEV TC-83 at MOI 0.1. Viral supernatants were collected 24 hours post-infection and assayed for viral replication by plaque
assays. Western blot results are displayed below the graph, indicating that GSK-3b expression was decreased following siRNA treatment.
doi:10.1371/journal.pone.0034761.g001
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3b was present in our IP material and not the IgG control. We
utilized a titration of the extract to show increased antigen
precipitation at fixed antibody concentrations (Panel C, Lanes 3–
5).
Presence of novel GSK-3b complexes in VEEV infected
cells
In recent years, we have focused on the discovery of new and
novel complexes present in infected, but not uninfected cells. For
that, we routinely use size exclusion chromatography to separate
proteins of interest from cells. Here, we prepared total extracts
from both VEEV infected and uninfected cells and loaded the
samples on a Superose 6 size-exclusion column in the presence of
500 mM salt (to increase specificity and detection of stable
complexes). Samples were fractionated in water soluble buffer over
,60 fractions followed by precipitation (to concentration dilute
fraction samples) and western blotted for the presence of GSK-3b.
As seen in Figure 5A, mock infected cells showed a predominant
band in fraction #40 with a molecular weight of ,200 kDa. This
most likely represents either homo- or hetero-dimer of GSK-3b
along with a possible chaperone protein. However, when looking
at the VEEV infected cells, we observed a very different profile.
For instance, the majority of the GSK-3b eluted in a larger
fraction #35 and a minor set of proteins was present in smaller
fractions #50 and #55. The larger fraction most likely represents
multimers of GSK-3b with possible unknown proteins bound and
smaller fraction represents monomer of GSK-3b. Actin protein
served as a control for both infected and uninfected fractions.
To assess whether the two fraction areas were kinase active, we
next immunoprecipitated the GSK-3b from neighboring fractions
and used them in an in vitro kinase reaction similar to experiments
designed in Figure 4. Data in Panel B indicates that GSK-3b from
smaller fraction #31 is kinase active when isolated from infected
cells. Fraction #41 showed similar kinase activity from both
infected and uninfected fractions and the smaller factions #51
showed kinase activity only from infected cells. These data suggest
that there are three distinct GSK-3b complexes in infected cells
and only one complex in uninfected cells.
We next examined the inhibition pattern of these GSK-3b
complexes using both BIO and BIOder. Results in Panel C show
that 0.1 uM concentration of compound did not inhibit the larger
GSK-3b complex from infected cells indicating that the drug
target may be the small complex from infected cells. Collectively,
these results imply that the three complexes from infected cells
have different IC50 and that the smaller (possible monomers) form
of GSK-3b may be the true target of BIO and BIOder.
BIOder treatment alters expression of apoptotic genes to
promote survival of U87MGs
Our results thus far suggest that BIOder is more effective than
the parent compound BIO in increasing viability of VEEV
infected cells. We asked the question whether any alterations in the
Figure 2. Identification of a BIO derivative that inhibits VEEV replication and CPE. A) U87MG astrocytes were pretreated for 2 hours with
DMSO or various BIO derivatives at 1 mM, infected with VEEV TC-83 at MOI 0.1, and post-treated with compounds. Twenty-four hours post infection
viral supernatants were collected and assayed for viral replication by q-RT-PCR. Compounds with an asterisk displayed greater than 1 log inhibition of
viral replication. The horizontal bar indicates the level of viral replication displayed by the DMSO control. B) U87MG astrocytes were treated with
DMSO or various BIO derivatives at 1 mM. Forty-eight hours post infection cell viability was measured by CellTiter Glo luminescence cell viability assay.
The horizontal bar indicates the cell viability displayed by the DMSO control (set to 100%). C) U87MG astrocytes were pretreated for 2 hours with
DMSO, BIO, #6, #8, #10, or #19 at 1 mM, infected with VEEV TC-83 at MOI 0.1, and post-treated with compounds. Twenty-four hours post infection
viral supernatants were collected and assayed for viral replication by plaque assays. D) BIO derivatives were assayed for their ability to inhibit VEEV
induced CPE. U87MG astrocytes were pretreated for 2 hours with DMSO or various BIO derivatives at 1 mM, infected with VEEV TC-83 at MOI 0.1, and
post-treated with compounds. Forty-eight hours post infection CPE was measured by MTT assay. Mock infected cells are displayed at 100% viability.
The horizontal bar indicates the cell viability displayed by the VEEV infected and DMSO control. Compound #6 has an asterisk as cells treated with it
displayed the greatest cell viability following VEEV infection.
doi:10.1371/journal.pone.0034761.g002
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Figure 3. Characterization of BIOder. A) Structure of BIO: 6-bromoindirubin-39-oxime and BIOder (#6): 6-bromo-5-methyl-1H-indole-2,3-dione 3.
B) U87MG astrocytes were pretreated for 2 hours with DMSO or BIOder (10, 1.0, and 0.1 mM), infected with VEEV TC-83 at MOI 0.1, and post-treated.
Twenty-four hours post-infection, supernatants were collected and analyzed by plaque assay to determine the amount of infectious virus released. C)
U87MG astrocytes were pretreated for 2 hours with DMSO or BIOder (10, 1.0, and 0.1 mM), infected with VEEV TC-83 at MOI 0.1, and post-treated.
Seventy hours post infection, CPE was measured by MTT assay. Mock infected cells are displayed at 100% viability. D) Uninfected U87MG astrocytes
were treated with BIOder (10, 1.0, and 0.1 mM), and cell viability determined by MTT assay. Untreated (UT) cells are displayed at 100% viability.
doi:10.1371/journal.pone.0034761.g003
Figure 4. BIO and BIOder inhibit GSK-3b in VEEV infected cells. A) U87MG astrocytes and B) Vero cells were pretreated for 2 hours with
DMSO, BIO (0.1 and 1.0 uM), or BIOder (0.1 and 1.0 uM), infected with VEEV TC-83 at MOI 0.1, and post-treated with DMSO, BIO, or BIOder. Mock
infected cells were treated with DMSO, 1 uM BIO, or 1 uM BIOder. Twenty-four hours post infection cells were collected and protein extracts
prepared. One mg of extract was IPed at 4uC overnight with GSK-3b antibody. The next day complexes were precipitated with A/G beads for two
hours at 4uC. IPs were washed twice with TNE buffer and kinase buffer. Phosphorylation reactions were performed with IP material and 200 ng of
glycogen synthase peptide 2 (Millipore) as substrate. Following incubation, samples were separated by SDS-PAGE, dried and subjected to analysis
using Molecular Dynamics Phosphor Imager software. C) Immunoprecipitation of GSK-3b and IgG control from titration of extracts followed by
staining. Constant amount of anti-GSK-3b or IgG Rabbit antibodies (10 mg each) were used for overnight precipitation using 10,100, and 1000 mg of
VEEV infected U87MG extracts. Samples were IPed overnight and next day Protein A and G were added, washed in TNE150 and 0.1% NP-40 and then
ran on a 4–20% followed by staining with coomassie blue. A dominant band of GSK-3b along with both heavy and light chains are stained.
doi:10.1371/journal.pone.0034761.g004
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expression patterns of pro- and anti-apoptotic genes following
BIOder treatment can be attributed to the increased survival of
infected cells. To answer that question, we performed RT-PCR
analysis of DMSO, BIO and BIOder treated cells 24 hours after
VEEV infection. Cells were pretreated with DMSO, BIO (1 mM)
and BIOder (1 mM) for two hours after which they were infected
with VEEV (MOI: 0.1). Cells were continued to be treated with
the inhibitors and DMSO for up to 24 hours post infection at
which point, the cells were lysed and total RNA extracted. RT-
PCR was carried out from DMSO and inhibitor treated cells with
primers to anti-apoptotic genes (Bcl-2, Survivin, cIAP and Bcl-XL)
and pro-apoptotic genes (BID, BAK, BAX and BAD). GAPDH
was measured as an internal control. While we did not observe any
significant changes in the expression of Bcl-1, cIAP and Bcl-XL,
our results demonstrated an increase in the expression of survivin
upon BIOder treatment (Figure 6A). We observed that although
treatment with BIO increased survivin expression, the fold
increase in expression following BIOder treatment was higher
over BIO (Figure 6B). We also observed a strong decrease in the
expression of the pro-apoptotic gene BID following BIOder
treatment (Figure 6A). Measurement of relative expression levels
between BIO and BIOder revealed stronger decrease in BID
expression after BIOder treatment (Figure 6B). Thus, our results
suggest that BIOder may contribute to increased viability of
VEEV infected cells by down regulating pro-apoptotic gene
expression (BID) and up regulating anti-apoptotic gene expression
(survivin).
BIOder inhibits VEEV induced mortality in mice
We next accessed the ability of BIO and BIOder to inhibit
VEEV induced death in vivo. As BIOder has never been tested in
vivo, we first performed a toxicity study with BIOder. Groups of 3
animals were treated subcutaneously with DMSO, BIOder
(10 mg/kg), BIOder (20 mg/kg) or BIOder (40 mg/kg) every
day for five days. Mice were monitored for signs of toxicity
including lethargy, ruffling of coats, and weight loss. No signs of
toxicity were observed in any of the treatment groups. The
average % mouse weight is shown in Figure 7A, where no
treatment group showed any weight loss and all groups gained
weight over the 10 day period. Based on these data, the dosage of
BIOder chosen for our infection study was 20 mg/kg as our in vitro
data demonstrated it to be a potent inhibitor, where as low as
0.1 mM of BIOder could inhibit VEEV induced CPE. A higher
dose of BIO (50 mg/kg) was chosen due to less potent inhibition of
VEEV and BIO being previously utilized in vivo at 50 mg/kg [43].
To determine if BIO or BIOder could protect against VEEV, the
VEEV TC-83 mouse model was utilized [36]. Groups of 10 mice
were treated subcutaneously with vehicle, BIO (50 mg/kg) or
BIOder (20 mg/kg) on Days 21, 1, 3, and 5 and monitored for 14
days. Vehicle treated animals had the expected 10% survival rate
whereas BIO treatment resulted in a 30% survival rate and
BIOder treatment a 50% survival rate (Figure 7B and 7C). Mean
time to death (MTD) between the control and BIOder treated
animals increased from 8 days to 10 days, and had a survival
differential of 40%, being statistically significant (p-value of 0.057).
In contrast, BIO MTD was 8 days and a survival differential of
20%, indicating no obvious significance (p-value of 0.733). Thus,
BIO does not show efficacy delivered subcutaneously against
VEEV TC-83 when the treatments are given as described above.
BIOder shows more promise than BIO. Increased efficacy may be
achieved with a more frequent treatment regimen (i.e. once daily),
higher dosage (i.e. 40 mg/kg), or different route of compound
administration (i.e. intraperitoneal). These data demonstrate that
BIOder treatment can reduce VEEV induced mortality.
Discussion
VEEV infection is thought to occur in two distinct phases, a
lymphotrophic phase, followed by a neurotrophic phase, both of
which are fairly well recapitulated in mouse models of disease [44].
VEEV infection spreads from the site of inoculation (usually the
footpad in mice) to the locally draining lymph node, causing
viremia and disseminating to other lymphoid organs. Viremia is
Figure 5. Presence of novel GSK-3b complexes in VEEV infected cells. A) Samples from both infected and uninfected cells were loaded on a
sizing column and separated in presence of a 500 mM salt buffer. No detergents were used during the chromatography steps. Each fraction (over a
range of 60 fractions) contained 500 mL and only 250 mL samples were precipitated, resuspend in low volume of TNE50 and 0.1% NP-40 (10 mL) and
ran on a gel for western blotting. Samples were western blotted for presence of GSK-3b and actin. B) GSK-3b IPs from fractions 31, 41, 51 (100 mL
each) were mixed with GSK-3b Ab (5 mg) overnight and washed next day first with RIPA buffer (16) and then TNE50 and 0.1% NP-40 (26) followed by
kinase buffer (36) prior to addition of substrate and 32P-ATP. Samples were ran on a gel, stained, destained (over 4 hrs), dried and then exposed to
phosphoImager cassette. Control immunoprecipitation from these fraction (50 uL each) were mixed and used for IP/Kinase using IgG (5 mg). C) IP/
kinase reactions were treated with either BIO or BIOder (0.1 uM or 1 mM) in vitro during the kinase reaction. Samples were ran on a gel and exposed
to phosphoImager cassette.
doi:10.1371/journal.pone.0034761.g005
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followed by the neurotropic phase of the disease [45,46]. Infection
of olfactory neuroepithelium as well as brain capillary endothelial
cells allows the virus to enter the brain [47], where VEEV infects
neurons and glial cells. Neuronal damage, which can be
contributed to both necrosis as well as apoptosis, is a critical
aspect of the brain lesions of VEEV infection in mice [21,48,49].
Non-infected neurons are also subject to bystander affects, as no
VEEV antigen could be found in a subset of dying neurons
[48,50]. As GSK-3b is an important neurologic modulator, in this
study we tested the hypothesis that inhibition of GSK-3b could be
protective against VEEV infection. Our data demonstrated that
GSK-3b is important for VEEV replication through the use of
small molecule inhibitors and siRNA experiments. Of the GSK-3b
inhibitors tested, BIO and the second generation BIOder
displayed the greatest inhibition of VEEV replication. BIO is a
synthetic derivative of the natural product, 6-bromoindirubin with
an IC50 of 5 nM against GSK-3b [37]. BIOder has an IC50 of
0.03 nM against GSK-3b [32]. The GSK-3 inhibitors SB-415286
and SB-216763 display IC50s of 78 nM and 34 nM respectively
[39]. It is important to note that BIO can also inhibit CDK5/p35,
CDK2/cyclin A, and CDK1/cyclin B complexes with higher
IC50s of 0.08, 0.30, and 0.32 mM respectively [37]. Therefore, it is
possible that at the concentrations used in our cell based assays,
other kinases were affected and contributed to the observed
inhibition. However, our siRNA data support a role of GSK-3b in
VEEV replication. In addition, we have presented novel data
indicating that the protein complexes in which GSK-3b is present,
change following VEEV infection. GSK-3b in mock infected cells
was present in a complex with a molecular weight of ,200 kDa,
which likely represents either homo- or hetero-dimer of GSK-3b
along with a possible chaperone protein. In contrast, VEEV
infected cells displayed three distinct complexes, a larger complex,
the ,200 kDa complex, and a small complex. We hypothesize
that the larger complex contains multimers of GSK-3b with
possible unknown proteins bound and the smaller fraction
represents monomer of GSK-3b. These data are novel as they
demonstrate a distribution of GSK-3b following infection, that is
not observed in uninfected cells. Furthermore, the monomer form
of GSK-3b from infected cells was more sensitive to both BIO and
BIOder treatment, suggesting that GSK-3b alone is more
accessible to the inhibitors and is in greater abundance following
infection.
Our results indicated that BIOder was able to inhibit VEEV
induced cell death. RT-PCR analysis showed upregulation of
survivin and downregulation of BID in BIOder treated VEEV
infected U87MG cells, suggesting that BIOder treatment and
GSK-3b inhibition alters apoptotic gene regulation. While there is
no published literature documenting GSK-3b’s alteration of
survivin and BID in particular, these results are in agreement
with the known role of GSK-3b in regulating apoptosis,
specifically the intrinsic pathway [51,52]. Lithium inhibition of
GSK-3b results in up-regulation of Bcl-2, the down-regulation of
p53, and inhibition of the c-Jun N-terminal kinase (JNK) pathway
[52]. Another interesting link between GSK-3b and apoptosis
involves the Bcl-2 family member, Mcl-1. Mcl-1 is an anti-
apoptotic protein whose degradation is induced through sequential
phosphorylation by JNK and GSK-3b [53,54,55]. Recently, p53
dependent apoptosis was shown to require GSK-3b [56], through
GSK-3b’s phosphorylation of the acetyltransferase Tip60. Tip60
acetylation of both p53 and histone H4 was shown to be important
for p53 dependent apoptosis and PUMA expression. In contrast,
GSK-3b can protect against TNF induced cytotoxicity [57,58]
and death receptor mediated extrinsic apoptotic pathways [52].
Therefore, the modulation of the apoptotic response by GSK-3b is
a balancing act that is most likely controlled by the targets of GSK-
3b phosphorylation in a cell type dependent and context specific
manner.
As the CNS is an immune privileged site, there is much interest
in understanding how VEEV enters and replicates within the
brain. A number of studies indicate that VEEV infection alters the
Figure 6. BIOder treatment alters expression of apoptotic genes to promote survival of U87MGs. A) U87MGs were treated with 1 mM
BIO, 1 mM BIOder, or DMSO and infected with VEEV TC-83. RNA was harvested from infected cells 24 hours post infection and analyzed by RT-PCR for
expression of the indicated anti- and pro-apoptotic genes. B) Band intensities corresponding to triplicate samples were quantified and represented as
fold change in gene expression over the DMSO control, with the DMSO control being set as a fold change of 1.0.
doi:10.1371/journal.pone.0034761.g006
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blood brain barrier (BBB) [59,60], which is composed of brain
capillary endothelial cells. Both fully virulent and VEEV replicons
alter the BBB [59,60]. VEEV infection induces a number of host
factors that mediate inflammation as well as alterations to the
BBB. For example, monocyte chemoattractant protein-1 (MCP-1),
which modulates the BBB potentially through causing alteration of
tight junction proteins in endothelial cells [61], is upregulated in
the brains of VEEV infected mice [62]. In addition, matrix
metalloproteinase-9 (MMP-9), which helps to maintain the BBB
[63,64], and intercellular adhesion molecule-1 (ICMA-1), a
molecular marker for BBB breakdown [59], were both upregu-
lated following VEEV infection [60]. Treatment of VEEV infected
mice with a small molecule compound inhibitor of MMP-9,
GM6001, delayed the opening of the BBB as well as the mean
time to death [60]. These results suggest that preventing access to
the brain, does not completely prevent VEEV pathogenesis.
Interestingly, inhibition of GSK3 in cultured brain microvascular
endothelial cells can suppress the production of multiple
inflammatory molecules and monocytes migration across cyto-
kine-stimulated cells [65]. In addition, inhibition of GSK3 in vivo
reduced leukocyte adhesion to brain endothelium under inflam-
matory conditions, suggesting that GSK3 promotes stabilization of
the BBB [65]. It is possible that BIOder may be influencing the
BBB, which coupled with the ability of BIOder to inhibit viral
replication, makes GSK3 inhibitors such as BIOder, promising
therapeutic candidates to protect against VEEV induced mortal-
ity.
Interestingly, BIOder was able to not only decrease VEEV
induced cell death, which is in line with the well documented
effects of GSK-3b inhibitors, but it was also able to decrease
VEEV replication. Therefore, it is possible that VEEV uses host
factors, including GSK-3b, as a part of its survival and replication
strategy. Our GSK-3b siRNA experiments support this hypoth-
esis. The modulation of the enzyme profile in the infected tissue
may induce damage to the tissue due to the secretion of cytokines
that are under GSK-3b control [25,66,67]. However, the
mechanism by which BIOder inhibits VEEV replication is
unclear. GSK-3b has numerous substrates, only some of which
may be biologically relevant [25]. Interestingly, many VEEV
proteins contain the GSK-3 consensus phosphorylation motif Ser/
ThrXXXSer/Thr, as determined using PhosphoMotif Finder
http://www.hprd.org/PhosphoMotif_finder [68]. Multiple pre-
dicted GSK-3 phosphorylation motifs are found within all the
non-structural proteins as well as the E2 and E1 proteins. Future
studies will focus on identification of the molecular mechanism by
which BIOder decreases VEEV replication.
One caveat of our current study is the use of VEEV TC-83.
TC-83 is a live attenuated vaccine derivative of the TrD strain of
VEEV that was derived by 83 serial passages of the virus in guinea
pig heart cells [34]. The genomes of TrD and TC-83 differ at 12
Figure 7. BIOder inhibits VEEV cell death in vivo. A) Female C3H/HeN mice were treated subcutaneously with either DMSO or various
concentration of BIOder (10 mg/kg, 20 mg/kg, 40 mg/kg) every day for 5 days. Mice were weighed daily and the average % of the mouse weight is
plotted in panel A. B) and C) Female C3H/HeN mice were infected intranasally with 56LD50 (26107 pfu) of VEEV TC-83. Groups of 10 mice were
treated SQ with vehicle, BIO (50 mg/kg) or BIOder (20 mg/kg) on days 21, 1, 3, and 5 and were monitored for survival for 14 days. Kaplan-Meier
curves for survival between DMSO and BIO (panel B). Kaplan-Meier curves for survival between DMSO and BIOder (panel C). Significance was
determined using Mantel-Cox Log-rank test. P-value of 0.057 between control and BIOder. This experiment was performed one time.
doi:10.1371/journal.pone.0034761.g007
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nucleotide positions and the attenuation of TC-83 has been
mapped to changes in the 59-untranslated region (UTR) and the
E2 envelope glycoprotein [35]. A recent study by Frolov and
colleagues indicated that the 59UTR mutation (G3A) affects the
secondary structure of the 59 end of the VEEV genome, resulting
in increased viral replication, without affecting viral translation
[69]. In vitro experiments with the model alphavirus, Sindbis virus,
indicated that the 39 end of the negative-strand genome can be
bound by host proteins [70]. Our current data indicate that GSK-
3b inhibition impedes VEEV replication; however it is unknown if
GSK-3b itself can interact with the VEEV genome or if it
modulates viral or host proteins that facilitates replication.
Additional studies will be critical to determine the mechanism
by which GSK-3b influences replication and if these results will
also translate to TrD VEEV replication. Along these lines, mouse
model studies with TC-83 have indicated that mice generally
display disease progression similar to those observed with VEEV
TrD, including cytokine production, high titer virus in the brain,
and disease symptoms such as hunching of the animals, weight
loss, and ruffling of the fur [36]. Some notable differences between
the models include reduced duration of viremia and lower
frequency of tissue infection outside the CNS [36,71]. Based on
these data, studies performed with TC-83 are likely to be
predictive of outcomes obtained with VEEV. However, future
studies both in vitro and in vivo must be performed to confirm the
importance of GSK-3b in wild-type VEEV infection.
Supporting Information
Figure S1 BIO and BIOder inhibit VEEV induced CPE.
U87MG astrocytes were pretreated for 2 hours with DMSO, BIO
(1.0 mM), or BIOder (1.0 mM), infected with VEEV TC-83 at
MOI 0.1, and post-treated with compounds. Forty-eight hours
post infection cells were imaged via light microscopy. Mock
infected cells are shown for comparison.
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